Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Amir Sharabi, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sthoeger Z, Sharabi A, Zinger H, Asher I, Mozes E. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1. Clin Immunol. 2018 Aug 28; 197:34-39. PMID: 30170030.
    View in: PubMed
  2. Li H, Tsokos MG, Bickerton S, Sharabi A, Li Y, Moulton VR, Kong P, Fahmy TM, Tsokos GC. Precision DNA demethylation ameliorates disease in lupus-prone mice. JCI Insight. 2018 Aug 23; 3(16). PMID: 30135300.
    View in: PubMed
  3. Gibor G, Ilan N, Journo S, Sharabi A, Dreyer J, Gertel S, Singh P, Menachem A, Snir N, Elkayam O, Vlodavsky I, Arad U. Heparanase is expressed in adult human osteoarthritic cartilage and drives catabolic responses in primary chondrocytes. Osteoarthritis Cartilage. 2018 Aug; 26(8):1110-1117. PMID: 29803826.
    View in: PubMed
  4. Sthoeger Z, Sharabi A, Asher I, Zinger H, Segal R, Shearer G, Elkayam O, Mozes E. The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients. Clin Immunol. 2018 Jul; 192:85-91. PMID: 29730433.
    View in: PubMed
  5. Sharabi A, Kasper IR, Tsokos GC. The serine/threonine protein phosphatase 2A controls autoimmunity. Clin Immunol. 2018 Jan; 186:38-42. PMID: 28736280.
    View in: PubMed
  6. Anis S, Sharabi A, Mina Y, Klein A, Cagnano E, Elkayam O, Gurevich T. Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System. Isr Med Assoc J. 2016 Oct; 18(10):630-632. PMID: 28471627.
    View in: PubMed
  7. Kasper IR, Apostolidis SA, Sharabi A, Tsokos GC. Empowering Regulatory T Cells in Autoimmunity. Trends Mol Med. 2016 09; 22(9):784-797. PMID: 27461103.
    View in: PubMed
  8. Litinsky I, Fireman E, Paran D, Polachek A, Broide A, Sharabi A, Anouk M, Elkayam O. Induced Sputum Analysis in Subjects With Systemic Sclerosis. Respir Care. 2016 Oct; 61(10):1369-73. PMID: 27274093.
    View in: PubMed
  9. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O. The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. J Rheumatol. 2016 09; 43(9):1749-54. PMID: 27252430.
    View in: PubMed
  10. Sharabi A. Editorial: Molecules Balancing Immunological Surveillance against Cancer and Autoimmune Diseases. Front Oncol. 2016; 6:86. PMID: 27148478; PMCID: PMC4828963.
  11. Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun. 2014 Nov; 54:60-71. PMID: 24958634.
    View in: PubMed
  12. Sthoeger Z, Zinger H, Sharabi A, Asher I, Mozes E. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-a in murine and human systemic lupus erythematosus. PLoS One. 2013; 8(3):e60394. PMID: 23555966; PMCID: PMC3610660.
  13. Sharabi A, Haran-Ghera N. Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res. 2011; 2011:269519. PMID: 22046558; PMCID: PMC3195280.
  14. Telerman A, Lapter S, Sharabi A, Zinger H, Mozes E. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations. J Neuroimmunol. 2011 Mar; 232(1-2):151-7. PMID: 21129786.
    View in: PubMed
  15. Lapter S, Ben-David H, Sharabi A, Zinger H, Telerman A, Gordin M, Leng L, Bucala R, Shachar I, Mozes E. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide. Immunology. 2011 Jan; 132(1):87-95. PMID: 20738420; PMCID: PMC3015078.
  16. Sharabi A, Laronne-Bar-On A, Meshorer A, Haran-Ghera N. Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev Res (Phila). 2010 Oct; 3(10):1265-76. PMID: 20719903.
    View in: PubMed
  17. Mozes E, Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev. 2010 Nov; 10(1):22-6. PMID: 20659591.
    View in: PubMed
  18. Sharabi A, Mozes E. Bcl-xL affects the development of functional CD4 Tregs. Arthritis Res Ther. 2010; 12(4):405. PMID: 20687901; PMCID: PMC2945028.
  19. Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. Adv Cancer Res. 2010; 107:1-37. PMID: 20399959.
    View in: PubMed
  20. Arazi A, Sharabi A, Zinger H, Mozes E, Neumann AU. In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+ CD25- cells in mice. PLoS One. 2009 Dec 24; 4(12):e8447. PMID: 20041142; PMCID: PMC2794381.
  21. Lapter S, Marom A, Meshorer A, Elmann A, Sharabi A, Vadai E, Neufeld A, Sztainberg Y, Gil S, Getselter D, Chen A, Mozes E. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum. 2009 Dec; 60(12):3744-54. PMID: 19950283.
    View in: PubMed
  22. Ben-David H, Sharabi A, Parameswaran R, Zinger H, Mozes E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis. Immunology. 2009 Oct; 128(2):245-52. PMID: 19740381; PMCID: PMC2767314.
  23. Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol. 2010 Jan; 30(1):34-44. PMID: 19756988.
    View in: PubMed
  24. Sharabi A, Sthoeger ZM, Mahlab K, Lapter S, Zinger H, Mozes E. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice. Clin Immunol. 2009 Oct; 133(1):61-8. PMID: 19631585.
    View in: PubMed
  25. Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun. 2010 Mar; 34(2):87-95. PMID: 19596183.
    View in: PubMed
  26. Sharabi A, Mozes E. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. Immunotherapy. 2009 May; 1(3):385-401. PMID: 20635958.
    View in: PubMed
  27. Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, Mozes E. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun. 2009 Aug; 33(1):77-82. PMID: 19346102.
    View in: PubMed
  28. Sthoeger ZM, Sharabi A, Dayan M, Zinger H, Asher I, Sela U, Mozes E. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol. 2009 Mar; 70(3):139-45. PMID: 19280712.
    View in: PubMed
  29. Parameswaran R, Ben David H, Sharabi A, Zinger H, Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol. 2009 May; 131(2):223-32. PMID: 19188092.
    View in: PubMed
  30. Sela U, Sharabi A, Dayan M, Hershkoviz R, Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology. 2009 Sep; 128(1 Suppl):e395-405. PMID: 19040426; PMCID: PMC2753948.
  31. Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol. 2008 Sep 01; 181(5):3243-51. PMID: 18713995.
    View in: PubMed
  32. Mozes E, Sela U, Sharabi A. A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action. Isr Med Assoc J. 2008 Jan; 10(1):40-2. PMID: 18300570.
    View in: PubMed
  33. Ben-David H, Sharabi A, Dayan M, Sela M, Mozes E. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc Natl Acad Sci U S A. 2007 Oct 30; 104(44):17459-64. PMID: 17956982; PMCID: PMC2077278.
  34. Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007 Oct 15; 179(8):4979-87. PMID: 17911582.
    View in: PubMed
  35. Elmann A, Sharabi A, Dayan M, Zinger H, Ophir R, Mozes E. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 2007 Jul; 56(7):2371-81. PMID: 17599765.
    View in: PubMed
  36. Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology. 2007 Jun; 121(2):248-57. PMID: 17346282; PMCID: PMC2265932.
  37. Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci U S A. 2006 Jun 06; 103(23):8810-5. PMID: 16735466; PMCID: PMC1482660.
  38. Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol. 2006 May; 119(2):146-55. PMID: 16503419.
    View in: PubMed
  39. Rapoport MJ, Sharabi A, Aharoni D, Bloch O, Zinger H, Dayan M, Mozes E. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol. 2005 Dec; 117(3):262-70. PMID: 16257268.
    View in: PubMed
  40. Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol. 2003 Dec; 56(6):635-8. PMID: 14616423; PMCID: PMC1884303.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sharabi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (169)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.